Rockwell Medical, Inc.
RMTI
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $31.5M
$7.99
▲ 0.00%
P/E
-20.97
Mkt Cap
$31.5M
52-Wk Range
$4.89–$18.50
52-Week Range
$4.89 - $18.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 49.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+20.8% over 3m
Quality
Thin
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RMTI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of -$0.34 vs -$0.24 consensus (-44.7% surprise). Revenue of $17.8M vs $17.8M expected (-0.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-44.7%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$17.3B
$17.8B
Margins · last 2Q
Gross
18.2%
Operating
-6.0%
Profit
-6.6%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 9, 2026
vs Industry
How RMTI stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.